Citius Pharmaceuticals (CTXR) Stock Price, News & Analysis

Company Overview

Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.

Key Stats

• Today's Range: $0.11 to $0.15
• 50-Day Range: $0.13 to $0.57
• 52-Week Range: $0.11 to $1.07
• Volume: 16.14 million shs
• Average Volume: 3.11 million shs
• Market Capitalization: $24.18 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.00
• Consensus Rating: Strong Buy

Citius Pharmaceuticals Stock Analysis - MarketRank™

Citius Pharmaceuticals scored higher than 58% of companies evaluated by MarketBeat, and ranked 457th out of 953 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Strong Buy

Consensus Rating

Citius Pharmaceuticals has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Citius Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Citius Pharmaceuticals are expected to grow in the coming year, from ($0.26) to ($0.18) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Citius Pharmaceuticals is -0.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Citius Pharmaceuticals is -0.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Citius Pharmaceuticals has a P/B Ratio of 0.23. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.52% of the outstanding shares of Citius Pharmaceuticals have been sold short.

Short Interest Ratio / Days to Cover

Citius Pharmaceuticals has a short interest ratio ("days to cover") of 10.5, which indicates bearish sentiment.

Change versus previous month

Short interest in Citius Pharmaceuticals has recently decreased by 5.07%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Citius Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Citius Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

6.52% of the outstanding shares of Citius Pharmaceuticals have been sold short.

Short Interest Ratio / Days to Cover

Citius Pharmaceuticals has a short interest ratio ("days to cover") of 10.5, which indicates bearish sentiment.

Change versus previous month

Short interest in Citius Pharmaceuticals has recently decreased by 5.07%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.02

News Sentiment

Citius Pharmaceuticals has a news sentiment score of 0.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for Citius Pharmaceuticals this week, compared to 1 article on an average week.

Search Interest

23 people have searched for CTXR on MarketBeat in the last 30 days. This is an increase of 283% compared to the previous 30 days.

MarketBeat Follows

13 people have added Citius Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 160% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Citius Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

15.00% of the stock of Citius Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 16.88% of the stock of Citius Pharmaceuticals is held by institutions.

CTXR Stock Analysis - Frequently Asked Questions

How have CTXR shares performed this year?

Citius Pharmaceuticals' stock was trading at $0.7565 at the start of the year. Since then, CTXR stock has decreased by 82.3% and is now trading at $0.1338.
View the best growth stocks for 2024 here.

How were Citius Pharmaceuticals' earnings last quarter?

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) released its earnings results on Monday, August, 12th. The company reported ($0.06) EPS for the quarter, missing analysts' consensus estimates of ($0.05) by $0.01.

When did Citius Pharmaceuticals' stock split?

Citius Pharmaceuticals's stock reverse split on the morning of Tuesday, November 26th 2024. The 1-25 reverse split was announced on Friday, November 22nd 2024. The number of shares owned by shareholders will be adjusted after the closing bell on Monday, November 25th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Who are Citius Pharmaceuticals' major shareholders?

Citius Pharmaceuticals' top institutional shareholders include Geode Capital Management LLC (1.04%), Wealth Advisory Solutions LLC (0.11%), Arkadios Wealth Advisors (0.11%) and Point72 Asia Singapore Pte. Ltd. (0.06%).
View institutional ownership trends.

How do I buy shares of Citius Pharmaceuticals?

Shares of CTXR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Citius Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Citius Pharmaceuticals investors own include Waste Connections (WCN), American Water Works (AWK), The RMR Group (RMR), Voyager Therapeutics (VYGR), AUO (AUOTY), DiamondRock Hospitality (DRH) and iShares Micro-Cap ETF (IWC).

Company Calendar

• Last Earnings: 8/12/2024
• Today: 11/23/2024
• Next Earnings (Estimated): 1/03/2025
• Fiscal Year End: 9/30/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CTXR
• CUSIP: N/A
• CIK: 1506251
• Web: www.citiuspharma.com
• Phone: (908) 967-6677
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $4.00
• High Stock Price Target: $4.00
• Low Stock Price Target: $4.00
• Potential Upside/Downside: +2,889.5%
• Consensus Rating: Strong Buy
• Rating Score (0-4): 3.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.24)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-32,540,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -44.65%
• Return on Assets: -39.39%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.75
• Quick Ratio: 6.75

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.58 per share
• Price / Book: 0.23

Miscellaneous

• Outstanding Shares: 180,730,000
• Free Float: 153,616,000
• Market Cap: $24.18 million
• Optionable: Optionable
• Beta: 1.66